The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al

Arthritis Care and Research

Volumn 68, Issue 5, 2016, Pages 723-724

  Calabrese, Leonard H ^a   Calabrese, Cassandra ^a   Kirchner, Elizabeth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT;

CHEMOTHERAPY; COMORBIDITY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEPATITIS B; HEPATITIS C; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; MEDICAL EXPERT; MEDICAL SOCIETY; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK BENEFIT ANALYSIS; VIRUS REACTIVATION; STANDARD; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEPATITIS B; HUMANS; REFERENCE STANDARDS; RHEUMATOLOGY; UNITED STATES;

EID: 84964460064     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22865     Document Type: Letter

References (9)

1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al., 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68: 1-25.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
3. Yazdany J, Calabrese L., Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken) 2010; 62: 585-9.
4. FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). URL: http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm.
5. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al., Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
6. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH., Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-11.
7. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ., Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable [editorial]. Ann Intern Med 2012; 156: 743-5.
8. AASLD/SDA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.
9. Colebatch-Bourn AN, Arden NK, Conaghan PG, Cooper C, Edwards CJ., Are guidelines good value for money? Rheumatology (Oxford) 2015; 54: 2121-3.